Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cylene initiates Phase I cancer trial
The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and pharmacokinetic properties of CX-4945 and to select the appropriate dose for Phase II
The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and pharmacokinetic properties of CX-4945 and to select the appropriate dose for Phase II
The company has also experienced a reorder rate of over 90%. “The promise of personalized medicine is quickly becoming a reality for patients with lung and colon cancer
SurgiSeal is said to be the first and only 2-octyl cyanoacrylate that does not require an activator. It is indicated for use in surgical and emergency applications. Cyanoacrylate
Velcura earlier completed a successful Phase Ia clinical trial of VEL-0230 in healthy individuals. Importantly, a rapid and significant reduction in bone resorption was observed in individuals treated
Mr Vazquez, who earned his bachelor of arts degree in biology and JD from the University of Puerto Rico, has assembled an experienced team of sales representatives and
CardioFit is intended as a treatment for New York Heart Association class II-III heart failure patients who have failed to achieve symptomatic improvement through standard evidence based management.
Participating in the financing were existing investors Claremont Creek Ventures and Sequoia Capital as well as new investor Alafi Capital. Matthew Rabinowitz, president and CEO of Gene Security
“I am pleased Howard has joined our R&D organization as we look to further build our robust pipeline in areas of significant unmet medical need in neuroscience,” said
This approval will enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers. Triphendiol
Prior to Auspex, Mr Grey was president and CEO of SGX Pharmaceuticals, which was recently acquired by Eli Lilly. Prior to joining SGX, Mr Grey was president and